Thierry Constans, MD; Elisabeth Diot, MD; Gérard Lasfargues, MD
To the Editors: Iloprost (Schering Corporation, Kenilworth, New Jersey), a stable prostacyclin analog, is a powerful vasodilator and platelet anti-aggregant. It has been shown to be clinically beneficial in Raynaud phenomenon (1, 2) as well as in atherosclerotic peripheral arterial disease (3), where transcutaneous oxygen pressure (PO2) correlates well with the degree of ischemia (4).
We studied the clinical effects of iloprost in 12 patients (mean age, 67 ± 10 [± SD] years) with well-documented scleroderma according to the American Rheumatism Association criteria (5); 7 patients had systemic sclerosis, 3 had sclerodactily, and 3 had the CREST syndrome. Seven patients
Constans T, Diot E, Lasfargues G. Iloprost for Scleroderma. Ann Intern Med. ;114:606. doi: 10.7326/0003-4819-114-7-606_1
Download citation file:
Published: Ann Intern Med. 1991;114(7):606.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use